Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
An update from NurExone Biologic ( (TSE:NRX) ) is now available.
NurExone Biologic Inc. announced promising preclinical results for its lead candidate, ExoPTEN, in treating glaucoma. The study demonstrated a reproducible, dose-dependent therapeutic effect, showing significant recovery of visual function in an optic nerve injury model. This advancement marks a critical step towards clinical trials, potentially offering a new treatment avenue for glaucoma and related vision loss conditions.
The most recent analyst rating on (TSE:NRX) stock is a Buy with a C$2.61 price target. To see the full list of analyst forecasts on NurExone Biologic stock, see the TSE:NRX Stock Forecast page.
More about NurExone Biologic
NurExone Biologic Inc. is a biopharmaceutical company focused on developing exosome-based regenerative therapies. The company is engaged in creating therapeutic solutions that leverage exosomes to deliver regenerative effects, particularly in the field of ophthalmology.
Average Trading Volume: 62,250
Technical Sentiment Signal: Strong Buy
Current Market Cap: C$58.07M
Learn more about NRX stock on TipRanks’ Stock Analysis page.